AU2017307306B2 - Intranasal pharmaceutical powder compositions - Google Patents

Intranasal pharmaceutical powder compositions Download PDF

Info

Publication number
AU2017307306B2
AU2017307306B2 AU2017307306A AU2017307306A AU2017307306B2 AU 2017307306 B2 AU2017307306 B2 AU 2017307306B2 AU 2017307306 A AU2017307306 A AU 2017307306A AU 2017307306 A AU2017307306 A AU 2017307306A AU 2017307306 B2 AU2017307306 B2 AU 2017307306B2
Authority
AU
Australia
Prior art keywords
instances
powder composition
active agent
pharmaceutical powder
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017307306A
Other languages
English (en)
Other versions
AU2017307306A1 (en
Inventor
Shunji Haruta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shin Nippon Biomedical Laboratories Ltd
Original Assignee
Shin Nippon Biomedical Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shin Nippon Biomedical Laboratories Ltd filed Critical Shin Nippon Biomedical Laboratories Ltd
Publication of AU2017307306A1 publication Critical patent/AU2017307306A1/en
Application granted granted Critical
Publication of AU2017307306B2 publication Critical patent/AU2017307306B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017307306A 2016-08-05 2017-08-04 Intranasal pharmaceutical powder compositions Active AU2017307306B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662371298P 2016-08-05 2016-08-05
US62/371,298 2016-08-05
PCT/IB2017/001121 WO2018025089A2 (en) 2016-08-05 2017-08-04 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
AU2017307306A1 AU2017307306A1 (en) 2019-01-17
AU2017307306B2 true AU2017307306B2 (en) 2022-06-30

Family

ID=60084012

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017307306A Active AU2017307306B2 (en) 2016-08-05 2017-08-04 Intranasal pharmaceutical powder compositions

Country Status (9)

Country Link
US (2) US10792253B2 (https=)
EP (1) EP3493789A2 (https=)
JP (2) JP2019527703A (https=)
KR (1) KR102489453B1 (https=)
CN (1) CN109640947A (https=)
AU (1) AU2017307306B2 (https=)
CA (1) CA3030359A1 (https=)
MX (1) MX2019001313A (https=)
WO (1) WO2018025089A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3049059T3 (da) 2013-09-24 2022-01-31 Satsuma Pharmaceuticals Inc Intranasal dhe formulering til behandlingen af hovedpine
US20200297734A1 (en) 2015-06-19 2020-09-24 Melt Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US20190142841A1 (en) * 2015-06-19 2019-05-16 Harrow Health, Inc. Pharmaceutical compositions and methods for anesthesiological applications
MX2018002895A (es) 2015-09-10 2018-07-06 Impel Neuropharma Inc Dispositivo de administracion nasal en linea.
EP3493789A2 (en) * 2016-08-05 2019-06-12 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical powder compositions
ES2907692T3 (es) 2017-12-29 2022-04-26 Celon Pharma Sa Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento
JP7317020B2 (ja) 2018-01-05 2023-07-28 インペル ファーマシューティカルズ インコーポレイテッド 精密嗅覚デバイスによるジヒドロエルゴタミンの鼻腔内送達
GB2581431A (en) * 2018-12-11 2020-08-19 Satsuma Pharmaceuticals Inc Compositions, devices, and methods for treating or preventing headaches
CN120284965A (zh) 2018-12-11 2025-07-11 小蜜橘制药公司 用于治疗或预防头痛的组合物、装置和方法
CN111346078B (zh) * 2018-12-21 2022-06-10 宜昌人福药业有限责任公司 一种他喷他多或其药学上可接受的盐经鼻粘膜给药的药物组合物及其制备方法和应用
CN113784703A (zh) * 2019-05-16 2021-12-10 株式会社新日本科学 经鼻施予用粉末制剂及其制造方法
AU2020283556A1 (en) * 2019-05-28 2022-01-06 The Charlotte-Mecklenburg Hospital Authority D/B/A Atrium Health Compositions and methods of making ribitol
CA3166250A1 (en) 2020-02-05 2021-08-12 Gregory G. Plucinski Drug products for intranasal administration and uses thereof
AU2021236662A1 (en) * 2020-03-18 2022-11-10 Cara Therapeutics, Inc. Oligosaccharide formulations of kappa opioid receptor agonists
PT3962455T (pt) 2020-05-18 2022-10-13 Orexo Ab Nova composição farmacêutica para entrega de fármacos
KR102563646B1 (ko) * 2021-04-06 2023-08-07 (주)메디코어 비강 세정용 분말 조성물의 제조방법 및 그에 따라 제조된 비강 세정용 분말 조성물
WO2022224030A1 (en) * 2021-04-20 2022-10-27 Sava Healthcare Ltd Dry powder inhalation (dpi) formulation
AR127780A1 (es) 2021-11-25 2024-02-28 Orexo Ab Nueva composición farmacéutica que comprende adrenalina
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
WO2024073588A1 (en) * 2022-09-28 2024-04-04 Board Of Regents, The University Of Texas System Respiratory dry powder delivery
CN115737568A (zh) * 2022-11-24 2023-03-07 东南大学 一种利培酮鼻用粉雾剂及其制备方法
EP4626438A2 (en) * 2022-12-01 2025-10-08 Pinata Holdings Inc. Inhalable hormone receptor agonist formulations
CN117003689A (zh) * 2023-09-28 2023-11-07 成都瑞尔医药科技有限公司 一种碘解磷定的晶型及其制备方法
WO2025101272A1 (en) * 2023-11-11 2025-05-15 Css Pharma L.L.C. Pharmaceutical composition for the acute treatment of migraine and other forms of headache

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169849A (en) * 1982-02-01 1992-12-08 Sandoz Ltd. Nasal pharmaceutical compositions
WO2004075824A2 (en) * 2003-02-28 2004-09-10 Britannia Pharmaceuticals Limited Pharmaceutical compositions for nasal delivery

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604486D0 (sv) * 1996-12-05 1996-12-05 Astra Ab Novel formulation
EP1108423B1 (en) * 1998-08-26 2005-03-30 Teijin Limited Powdery pernasal compositions
US20030198669A1 (en) * 2001-07-05 2003-10-23 R.T. Alamo Ventures I, Llc Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
WO2006016530A1 (ja) * 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
PL1824450T3 (pl) * 2004-10-11 2013-04-30 Nasaleze Patents Ltd Kompozycje do podawania donosowego
JPWO2006064906A1 (ja) * 2004-12-17 2008-06-12 小野薬品工業株式会社 非晶質性組成物
US8337817B2 (en) * 2006-12-26 2012-12-25 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
WO2009095684A1 (en) 2008-02-01 2009-08-06 Vectura Limited Pulmonary formulations of triptans
US9192578B2 (en) 2008-08-20 2015-11-24 Board Of Regents, The University Of Texas System Hot-melt extrusion of modified release multi-particulates
SG10201607849TA (en) 2009-04-24 2016-11-29 Iceutica Pty Ltd Production of encapsulated nanoparticles at commercial scale
US20100291221A1 (en) * 2009-05-15 2010-11-18 Robert Owen Cook Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
WO2011013003A2 (en) 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
CA2825541C (en) 2011-01-31 2020-06-02 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
EP2601973A1 (en) 2011-12-09 2013-06-12 Laboratoires SMB SA Dry powder formulation of azole derivative for inhalation
HUE050050T2 (hu) 2013-03-04 2020-11-30 Besins Healthcare Lu Sarl Hordozórészecskékhez kötõdõ hatóanyag nanorészecskéket tartalmazó száraz gyógyászati kompozíciók
DK3049059T3 (da) 2013-09-24 2022-01-31 Satsuma Pharmaceuticals Inc Intranasal dhe formulering til behandlingen af hovedpine
RU2570092C2 (ru) 2013-09-30 2015-12-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Петрозаводский государственный университет" Способ выявления различий структурного состояния целлюлозы
EP3493789A2 (en) 2016-08-05 2019-06-12 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical powder compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169849A (en) * 1982-02-01 1992-12-08 Sandoz Ltd. Nasal pharmaceutical compositions
WO2004075824A2 (en) * 2003-02-28 2004-09-10 Britannia Pharmaceuticals Limited Pharmaceutical compositions for nasal delivery

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JI-EON KIM ET AL: DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol. 40, no. 6, 3 April 2013 (2013-04-03), US, pages 743 - 748, XP055425476, ISSN: 0363-9045, DOI: 10.3109/03639045.2013.782503 *

Also Published As

Publication number Publication date
WO2018025089A3 (en) 2018-03-15
US11872314B2 (en) 2024-01-16
JP2019527703A (ja) 2019-10-03
WO2018025089A2 (en) 2018-02-08
MX2019001313A (es) 2019-09-26
CN109640947A (zh) 2019-04-16
BR112019002371A2 (pt) 2019-06-04
RU2019105698A3 (https=) 2020-11-18
KR102489453B1 (ko) 2023-01-16
EP3493789A2 (en) 2019-06-12
JP2022078268A (ja) 2022-05-24
US20200397702A1 (en) 2020-12-24
US10792253B2 (en) 2020-10-06
RU2019105698A (ru) 2020-09-08
JP7366178B2 (ja) 2023-10-20
US20180036247A1 (en) 2018-02-08
CA3030359A1 (en) 2018-02-08
KR20190038589A (ko) 2019-04-08
AU2017307306A1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
US11872314B2 (en) Pharmaceutical compositions
ES2538460T3 (es) Nueva composición farmacéutica resistente al abuso para el tratamiento de la dependencia de opioides
US20250319081A1 (en) Compositions, Devices, and Methods for Treating or Preventing Headaches
US20100129443A1 (en) Non-abusable pharmaceutical composition comprising opioids
US20080248110A1 (en) Pharmaceutical Compositions Useful in the Treatment of Pain
EP4008307A1 (en) Intranasal dhe formulation for the treatment of headache
CN101394863A (zh) 小体积口腔经粘膜剂型
LT4976B (lt) Intranazalinio morfino turinčios farmacinės kompozicijos ir jų panaudojimas
RU2818086C2 (ru) Интраназальные фармацевтические порошковые композиции
BR112019002371B1 (pt) Composição farmacêutica intranasal em pó compreendendo partículas secas por aspersão, uso da referida composição para tratar ou prevenir dor de cabeça, dispositivo contendo a referida composição e método de preparo da referida composição farmacêutica
HK40055558A (en) Compositions, devices, and methods for treating or preventing headaches
HK40076888A (en) Intranasal dhe formulation for the treatment of headache
AU2006228297A1 (en) New pharmaceutical compositions useful in the treatment of pain

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)